1. 精神疾病相关代谢综合征患者 药物性代谢异常：长期使用抗精神障碍药物（如奥氮平、喹硫平、米氮平、丙戊酸钠等）导致体重增 加、胰岛素抵抗、血脂异常的患者。 共病代谢疾病：精神分裂症、双相障碍等患者合并糖尿病、高血压、非酒精性脂肪肝等代谢性疾病，需 协同干预。 新京报讯（记者戴轩）精神疾病与体重异常常相伴而生。记者从北京安定医院获悉，该院体重管理与营 养多学科联合门诊将于4月29日开诊。 精神疾病与体重异常常相伴而生。精神疾病患者面临肥胖、代谢异常或营养不良等问题，这与药物副作 用、情绪性进食、代谢紊乱等密切相关。 为积极响应国家卫健委"体重管理年"行动号召，切实解决患者"治病易发胖、减重难坚持"的困扰，北京 安定医院整合多学科资源，正式开设"体重管理与营养多学科联合门诊"，为精神疾病合并体重问题的患 者提供"一站式"干预。该门诊由精神科、营养科、中医科、药事科等多团队提供服务。 接诊人群包括： 复发高危人群：通过体重管理降低代谢负担（如内脏脂肪堆积促炎状态），间接减少精神症状复发风 险。 生活方式重建：慢性精神疾病患者（如稳定期精神分裂症）的社区营养支持。 该门诊出诊时间为每周二上午8:00-12:00。出 ...

在随后举行的"艺术疗愈促进身心健康的探索与实践"研讨会上，第十二届全国政协社会和法制委员会副 主任张世平指出，要准确把握职工心理问题的差异性，维护职工心理健康是一项系统工程，政府应把心 理健康的系统化建设摆在更加突出的位置，进一步完善精神卫生相关法律法规，加大对心理健康服务的 政策倾斜和资金支持，提升精神卫生领域的科技创新能力；医院要注重关口前移，重视科学防控，着力 抓好前端预防、后端康复的工作；工会要注重维护职工健康权益，加强职工健康教育，倡导科学生活方 式，重视心理专业人才的培养。 北京小汤山医院党委书记张金霞介绍，小汤山医院具有得天独厚的自然环境，是开展人文艺术疗法、引 领新时代健康管理新理念和新模式的不二之选。依托独特的自然因子，医院致力于建立一套集温泉水 疗、森林康养、中医养护、药膳食疗、运动干预、物理治疗、艺术疗愈等于一体的全要素自然疗法体 系，打造健康中国的"小汤山模式"。 校对 卢茜 新京报讯（记者张秀兰）在"五一"国际劳动节来临之际，北京小汤山医院举办了"向劳动者致敬"主题活 动，面向社会发布职工身心健康关爱项目，包含健康管理、中医养生等九大特色板块，致力于从身体到 心理全方位守护职工健康。 ...

Financial Data and Key Metrics Changes - In the first quarter of 2025, diluted earnings per share, as adjusted, increased more than 20% year-over-year to $6.45 [9] - Adjusted EBITDA grew 11.3% over the prior year quarter, with an adjusted EBITDA margin improvement of 110 basis points [20][22] - Cash flow from operations was $1.65 billion in the quarter, with a decrease attributed to working capital changes [24] Business Line Data and Key Metrics Changes - Inpatient admissions grew 2.6% year-over-year, equivalent admissions increased 2.8%, and emergency room visits rose by 4% [10] - Same facilities revenue grew almost 6%, driven by volume increases and approximately 3% higher revenue per equivalent admission [11] - Surgical volumes were mixed, with inpatient surgeries slightly up and outpatient cases down [10][33] Market Data and Key Metrics Changes - Same-facility managed care equivalent admissions increased by 5.4% compared to the prior year quarter, while same-facility equivalent exchange admissions surged by 22.4% [20] - Exchange volume represented about 8% of equivalent admissions and approximately 10% of revenues for the quarter [108] Company Strategy and Development Direction - The company is focused on maintaining operational discipline while continuing to invest in its strategic agenda, including increasing the number of facilities by 3.3% [12][13] - Capital allocation strategy includes $991 million in capital expenditures, $225 million in share repurchases, and $180 million in dividends [25] - The company is investing heavily in technology and digital transformation to improve operational efficiency and clinical care [132][133] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the overall demand for healthcare services and the company's ability to navigate through uncertain policy environments [14][18] - The company is developing plans to address potential adverse impacts from health policy changes and tariffs, drawing from experiences during the COVID-19 pandemic [17][75] - Management remains optimistic about maintaining market share gains and operational efficiencies despite competitive pressures [100][101] Other Important Information - The company reaffirmed its guidance ranges for the full-year 2025, indicating confidence in its operational performance [26] - The company reported an $18 million increase in net benefits related to Medicaid in the first quarter of 2025 compared to the prior year quarter [23] Q&A Session Summary Question: Any major changes in assumptions embedded in the reiteration of guidance? - Management stated that the first quarter performance was solid, and guidance for 2025 remains appropriate [31] Question: How do you get that much leverage this quarter? - Management explained that operating leverage is created by pushing more volume through the organization, which improves profitability and margins [42] Question: Can you clarify the revenue per adjusted admission increase? - Management noted that the increase was driven by payer mix trends and improved acuity, with managed care positioning improving year-over-year [55][59] Question: Any changes with MA plan behavior denials? - Management indicated that there were no significant changes in denials and underpayments that materially impacted financial results [68] Question: How is the surgical schedule and block time utilization looking? - Management believes that demand for healthcare will remain strong, with expectations for surgical volumes to recover [126] Question: Can you speak to your technology agenda? - Management highlighted significant investments in technology and digital transformation to enhance operational efficiency and clinical care [132][133]

Core Viewpoint - The pharmacy department in hospitals has undergone significant changes, shifting from a profit center to a cost center and now to a department focused on compliance with various drug-related assessments and regulations [2][30]. Group 1: Changes in Pharmacy Department's Role - The pharmacy department was once a key profit center for hospitals but transformed into a cost center after the cancellation of drug markups in public hospitals in 2017 [2][30]. - The department now faces a multitude of drug-related assessment indicators, such as antibiotic usage intensity and basic drug ratio, complicating its operational landscape [3][4]. - The pharmacy department's responsibilities have expanded to include compliance with both clinical needs and regulatory requirements, creating a complex work environment [4][6]. Group 2: Challenges Faced by Pharmacy Departments - Pharmacy department heads, like Wang Jun, report feeling overwhelmed by the increasing number of policies and assessments they must navigate, often leading to conflicts between clinical needs and regulatory demands [6][9]. - Issues such as drug shortages, particularly for commonly used medications, have become a frequent challenge, leading to patient complaints and added pressure from hospital administration [8][9]. - The pharmacy department must balance various conflicting demands from regulatory bodies, clinical staff, and patients, making their role increasingly complex [17][19]. Group 3: Evolving Assessment Metrics - The performance assessment metrics for pharmacy departments have become more detailed and stringent, with a focus on antibiotic usage and cost management [14][15]. - The introduction of new metrics, such as the average drug cost per outpatient/inpatient, has added to the pressure on pharmacy departments to manage costs effectively while ensuring compliance [15][22]. - The shift in focus from drug ratios to cost metrics reflects a broader trend in healthcare towards more comprehensive performance evaluations [15][22]. Group 4: Future Implications - The pharmacy department's role is evolving from a cost center to a compliance support function, emphasizing the need for effective communication and professional knowledge to navigate complex regulations [26][30]. - As the healthcare landscape continues to change, pharmacy departments must adapt to new policies and assessment criteria, which may lead to further challenges in drug management and patient care [30].

对于患者和医院双方，新政策会带来哪些经济或就医流程上的变化？今日，记者采访了试点医院之一北 京清华长庚医院的相关负责人，对此进行了解答。 关注1：哪些群体在政策范围内？ 排上了择期手术，住院之前就可开展检查，且相关费用可纳入住院费用结算——近日，北京市医疗保障 局发布了开展"预住院"费用医保支付试点工作的通知，试点将从4月26日起执行。 通知指出，试点医疗机构范围由北京市医疗保险事务管理中心确定。新京报记者从多位业内人士处了解 到，本次有5家综合医院参与了试点。 关注3：哪些病种纳入试点？ 据规定，"预住院"病种范围包括诊断明确、病情相对稳定且经评估符合住院指征行择期手术的病种。具 体病种范围由试点医疗机构自行制定。 "这个政策主要针对择期手术的患者，他们术前发生的一系列相关费用，虽然在门诊执行，但可以转到 住院费用中，以住院的医保支付比例进行报销。"北京清华长庚医院医事科科长张燕向新京报记者介 绍。 根据北京市医保局的通知，北京市基本医疗保险定点医疗机构，在保障医疗质量安全的前提下，对诊断 明确、病情相对稳定且经评估符合住院指征行择期手术的参保人员，通过办理"预住院"完成术前检查检 验，相关费用待参保人员正 ...

Group 1 - Yilida plans to repurchase shares worth 30 to 50 million yuan for employee stock ownership plans, with a maximum price of 6.5 yuan per share [1] - Yinglian shares two major shareholders plan to reduce their holdings by up to 5% [1][2] - Zhongbing Hongjian reports a net loss of 327 million yuan for 2024, with a revenue decline of 25.29% [2][3] Group 2 - Zhongke Electric reports a net profit increase of 626.56% for 2024, with a revenue growth of 13.72% [3][4] - Yong'an Futures reports a net profit decline of 21.07% for 2024, with a revenue decrease of 8.76% [5][6] - Yongjie New Materials reports a net profit increase of 34.28% for 2024, with a revenue growth of 24.71% [7][8] Group 3 - Xibu Securities reports a net profit increase of 20.38% for 2024, despite a revenue decline of 2.64% [9][10] - Jinying Heavy Industry reports a net profit decline of 35.54% for 2024, with a slight revenue increase of 1.13% [10][11] - Haineng Industry reports a net profit decline of 40.45% for 2024, despite a revenue growth of 16.26% [12][13] Group 4 - Penghui Energy reports a net loss of 252 million yuan for 2024, with a revenue increase of 14.83% [14][15] - Weiming Pharmaceutical reports a net loss of 137 million yuan for 2024, with a revenue decline of 16.14% [16][17] - Huachang Technology reports a net profit increase of 184.26% for 2024, with a revenue growth of 6.74% [18][19] Group 5 - Ancar Detection reports a net loss of 213 million yuan for 2024, with a revenue decline of 3.05% [20][21] - Saiwei Intelligent reports a net loss of 507 million yuan for 2024, with a significant revenue decline of 68.03% [22][23] - Qinglong Pipe Industry reports a net profit increase of 976.43% for 2024, with a revenue growth of 36.71% [24][25] Group 6 - Huayin Electric reports a net loss of 113 million yuan for 2024, with a revenue decline of 16.00% [26][27] - Zhongqi New Materials reports a net profit decline of 61.59% for 2024, with a revenue decrease of 22.88% [28][29] - Guangzheng Eye Hospital reports a net loss of 175 million yuan for 2024, with a revenue decline of 16.94% [30][31] Group 7 - Zhenlan Instrument reports a net profit increase of 2.16% for 2024, with a revenue growth of 11.63% [32][33] - Zaiseng Technology reports a net profit increase of 137.99% for 2024, despite a revenue decline of 10.87% [34][35] - Haitai High-tech reports a net profit increase of 51.34% for 2024, with a revenue growth of 25.26% [36][37] Group 8 - Runze Technology reports a net profit increase of 1.62% for 2024, with a revenue growth of 0.32% [38][39]

华夏时报（www.chinatimes.net.cn）记者 于娜 北京报道 "我们医院目前正常接诊，没有变化。"北京三博脑科医院的一位内部人员告诉《华夏时报》记者。对于董事长张 阳被留置、立案调查一事给公司经营及控制权带来的影响等问题，《华夏时报》记者联系采访三博脑科，截至发 稿未收到回复。 民营医院大佬"落马" 公开资料显示，张阳于1965年10月出生，高级工商管理专业，硕士研究生学历。2003年，张阳与北京天坛医院三 位博士生导师共同创立了三博脑科。 三博脑科注册地为北京市海淀区，主要从事以神经专科为特色的临床医疗服务，主要产品包括医疗服务、药品、 供应链、其他业务。目前，三博脑科在北京、重庆、昆明、福建、成都和河南共运营了8家医院。 张阳于2004年至2025年3月，任三博脑科总经理；2014年至今，任三博脑科董事长。同时，张阳担任中国非公立医 疗机构协会副会长、中国医院协会民营医院管理分会副会长、北京市非公立医疗机构协会终身名誉会长。 据2024年年报披露，张阳直接持有公司股份10.59%，与于春江、栾国明、石祥恩为一致行动人，构成对公司的共 同控制。公司2023年4月27日公告的《招股说明书》披露了 ...

文/西风 4月21日晚上，三博脑科医院管理集团股份有限公司（301293）公告：现收到内蒙古自 治区监察委员会签发关于公司控股股东、实际控制人之一暨董事长张阳先生 个人的《留置通知书》和《立案通知书》。张阳先生1965年10月出生，如今已近60岁，现任公司董事长，中国非公立医疗机构协会副会长、中国医院协会民营医 院管理分会副会长、北京市非公立医疗机构协会终身名誉会长。三博脑科2023年5月5日上市，上市未满2年，实控人兼董事长被留置、立案调查了！ 公司注册地北京市海淀区，主要从事以神经专科为特色的临床医疗服务，目前在北京、重庆、昆明、福建、成都和河南共运营了8家医院。 2022年、2023年、2024年，公司分别实现营业收入10.70亿元、13.13亿元、14.29亿元，扣非归母净利润分别为0.5207亿元、0.9360亿元、0.9431亿元。 | 财务指标 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | | --- | --- | --- | --- | --- | --- | | 审计意见 | | | 标准无保留意见 | ...

经济观察报记者张铃 2023年5月，三博脑科上市，目前，其总市值为93亿元。据三博脑科2024年年报，目前其共运营了8家医 院，分别位于北京、重庆、昆明、福建、成都和河南。三博脑科未在此次对张阳实施留置的内蒙古自治 区运营医院。 三博脑科上市后不久，张阳在接受经济观察报专访时提到，三博脑科不收患者红包，不靠药品耗材增加 收入，摒弃各种暗箱操作，每年拒收的红包数额达数百万元，同时给到医生高于公立医院的阳光收入。 2025年3月4日，三博脑科发布公告称，根据其经营发展及管理需要，张阳辞去总经理职务，仍担任董 事、董事长及董事会战略委员会主任委员职务。 4月21日晚，三博脑科（301293）(301293.SZ)公告称，其收到内蒙古自治区监察委员会签发的关于其控 股股东、实际控制人之一暨董事长张阳的个人《留置通知书》和《立案通知书》。 经济观察报记者致电张阳个人手机，显示已关机。他最新的朋友圈更新于4月16日，内容是他转发的家 乡某视频号对他的采访。 4月21日晚，三博脑科多名内部人士告诉经济观察报，他们是在看到公告后才知晓张阳被留置的消息， 他们对此消息感到意外。其中一名内部人士说："就在前两天，他还接受了央媒采 ...

Core Viewpoint - Peking University First Hospital (referred to as "PKU Hospital") is launching the construction of fertility-friendly and child-friendly hospitals, aligning with national policies to support maternal and child health and contribute to a fertility-friendly society [1][4] Group 1: Hospital Initiatives - PKU Hospital is one of the first "mother-baby friendly hospitals" in Beijing, establishing specialized centers for reproductive medicine and pediatrics to enhance maternal and child health services [2] - In 2024, PKU Hospital treated 786,000 women and children, with 65% of pediatric inpatient cases being critical, and recorded 6,614 deliveries, with 95% being high-risk pregnancies [2] - The hospital has implemented an integrated delivery room (LDR) model to provide comprehensive services from labor to postpartum care, ensuring safety and privacy for mothers and infants [2] Group 2: Child-Centric Facilities - The Children's Medical Center at PKU Hospital has expanded its outpatient and inpatient facilities, increasing the pediatric outpatient area by approximately 11.93 times to 9,973 square meters [3] - The center features child-friendly amenities such as play areas, reading corners, and specialized facilities to enhance the hospital experience for children [3] - PKU Hospital has improved its neonatal rescue capabilities, achieving a success rate of over 95% in neonatal intensive care, and has established a 24-hour referral hotline for critical cases [3] Group 3: Strategic Development - To effectively advance the construction of fertility-friendly and child-friendly hospitals, PKU Hospital has developed an implementation plan and formed specialized working groups to ensure efficient and orderly progress [4] - The recent conference marks a significant step in enhancing services tailored to the health needs of women and children, aiming to create a more efficient, safe, and warm healthcare environment [4]